Since 1946 when mechlorethamine hydrochloride (nitrogen mustard), an alkylating agent, was first reported to exert a suppressive effect on rapidly dividing cells,1 many new alkylating agents have been synthesized. A few have weathered clinical trial and have proven their effectiveness in the control of chronic leukemias and lymphomas and palliation of patients with malignant tumors. These include triethylene melamine (T.E.M.), triethylene thiophosphoramide (thio-TEPA) and chlorambucil (Leukeran). Recently Arnold, Bourseaux, and Brock2 reported the development of a new alkylating agent, cyclophosphamide* (N,N-bis (β-chloroethyl)-N, O-propylene phosphoric acid ester diamide monohydrate) which promised certain advantages over existing alkylating agents. Clinical trials conducted by Gross and Lambers3,4 in Germany showed the beneficial effects in 9 of 23 patients with malignant lymphoma.
Cyclophosphamide (Cytoxan*) was made available in this country for clinical trial in 1959. An early report by Coggins, Ravdin, and Eisman6 suggested its continued appraisal in
WALL RL, CONRAD FG. Cyclophosphamide Therapy: Its Use in Leukemia, Lymphoma and Solid Tumors. Arch Intern Med. 1961;108(3):456–482. doi:10.1001/archinte.1961.03620090128016
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: